Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2014 by Acetylon Pharmaceuticals Incorporated
Information provided by (Responsible Party):
Acetylon Pharmaceuticals Incorporated Identifier:
First received: November 20, 2013
Last updated: July 21, 2014
Last verified: July 2014

Phase 1b: To evaluate the side effects and determine the best dose of ACY-1215 in combination with Pomalidomide and low-dose dexamethasone in patients with relapsed-and-refractory multiple myeloma.

Phase 2: To determine the overall response rate of ACY-1215 in combination with Pomolidomide and low-dose dexamethasone in patients with relapsed-and-refractory multiple myeloma

Condition Intervention Phase
Multiple Myeloma
Drug: ACY-1215 in combination with pomalidomide and dexamethasone
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 1b/2 Multicenter, Open Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dex in Patients With Relapsed-and-Refractory Multiple Myeloma

Resource links provided by NLM:

Further study details as provided by Acetylon Pharmaceuticals Incorporated:

Primary Outcome Measures:
  • Phase 1b: MTD and dosing schedule of ACY-1215 administered in combination with pomalidomide and low-dose dexamethasone in patients with MM [ Time Frame: 28 days ] [ Designated as safety issue: Yes ]
  • Phase 2: Overall response rate of ACY-1215 in combination with pomalidomide and dexamethasone in patients with relapsed-and-refractory multiple myeloma [ Time Frame: Every 56 days for the duration on treatment, an estimated average of 4 months ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Phase 1b & 2: Safety assessed by type, frequency and severity of AEs and relationship of AEs to study drug [ Time Frame: Upon completion of a 28 day treatment cycle and for the duration of treatment, an estimated average of 4 months. ] [ Designated as safety issue: Yes ]
  • Phase 1b and 2: Efficacy assessed by time to response, duration of response, time to progression, progression free survival, and objective response as assessed by a central adjudication committee [ Time Frame: Every 56 days on treatment, estimated average of 4 months. Survival will be evaluated every 4 months for up to 5 years. ] [ Designated as safety issue: Yes ]
  • Phase 1b: Plasma levels of ACY-1215 and plasma levels of pomalidomide [ Time Frame: Up to 8 days post first dose ] [ Designated as safety issue: Yes ]
  • Phase 1b: Exposure response of treatment including biomarkers relatating to intracellular protein acetylation, protein levels, mRNA and microRA expression profiles. [ Time Frame: Up to 24 hours post first dose ] [ Designated as safety issue: Yes ]

Other Outcome Measures:
  • Phase 2: Relationship between response to treatment and any cytogenetic abnormalities [ Time Frame: Duration on study, estimated average of 4 months ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 100
Study Start Date: November 2013
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ACY-1215 + pomalidomide + dexamethasone Drug: ACY-1215 in combination with pomalidomide and dexamethasone
Other Name: Pomalyst


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Must have a documented diagnosis of multiple myeloma and have relapsed and refractory disease. Patients must have received at least 2 lines of prior therapies. Patients must have relapsed after having achieved at least stable disease (SD) for at least one cycle of treatment to at least one prior regimen and then developed progressive disease (PD). Patients must also have documented evidence of PD during or within 60 days (measured from the end of the last cycle) of completing treatment with the last anti-myeloma drug regimen used just prior to study entry (refractory disease).
  • Must have undergone prior treatment with at least 2 cycles of lenalidomide and at least 2 cycles of a proteasome inhibitor (either in separate regimens or within the same regimen).
  • Must not be a candidate for autologous stem cell transplant (ASCT), has declined the option of ASCT, or has relapsed after prior ASCT.
  • Must have measurable levels of myeloma paraprotein in serum (≥ 0.5 g/dL) or urine (≥ 0.2 g/24 hours).
  • Must have Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2.
  • Females of child bearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL within 10 - 14 days prior to, and again within 24 hours of starting pomalidomide and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking pomalidomide. FCBP must also agree to ongoing pregnancy testing. Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a vasectomy. All patients must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure. See Appendix 9.3.1 Risks of Fetal Exposure, Pregnancy Testing Guidelines and Acceptable Birth Control Methods, AND also Appendix 9.3.2 Education and Counseling Guidance Document.
  • Must be able to take acetylsalicylic acid (ASA) (81 or 325 mg) daily as prophylactic anticoagulation. Patients intolerant to ASA may use low molecular weight heparin. Lovenox is recommended. Coumadin will be allowed provided the patient is fully anticoagulated, with an international normalized ratio (INR) of 2 to 3.

Exclusion Criteria:

  • Pregnant or lactating females.
  • Prior therapy with HDAC inhibitor
  • Any of the following laboratory abnormalities:

    • ANC < 1,000/µL
    • Platelet count < 75,000/ µL for patients in whom < 50% of bone marrow nucleated cells are plasma cells; or a platelet count < 30,000/ µL for patients in whom ≥ 50% of bone marrow nucleated cells are plasma cells
    • Serum creatinine ≥ 3.0 mg/dL
    • Serum glutamic oxaloacetic transaminase (SGOT)/ aspartate aminotransferase (AST), or serum glutamic pyruvic transaminase (SGPT)/ alanine aminotransferase (ALT) > 3.0 × ULN
    • Serum total bilirubin > 2.0 mg/dL
  • Prior history of malignancies, other than MM, unless the patient has been free of the disease for ≥ 3 years. Exceptions include the following:

    • Basal or squamous cell carcinoma of the skin
    • Carcinoma in situ of the cervix or breast
    • Incidental histologic finding of prostate cancer (TNM stage of T1a or T1b)
  • Corrected QT interval using Fridericia's formula (QTcF) value > 480 msec at Screening and pre-dose on C1D1; family or personal history of long QTc syndrome or ventricular arrhythmias including ventricular bigeminy; previous history of drug-induced QTc prolongation or the need for treatment with medications known or suspected of producing prolonged QTc intervals on electrocardiogram (ECG).
  • Known human immunodeficiency virus (HIV), hepatitis B virus (HBV) and/or hepatitis C virus (HCV) infection.
  • Hypersensitivity to thalidomide, lenalidomide, or dexamethasone.
  • Peripheral neuropathy ≥ Grade 2.
  • Radiotherapy or systemic therapy (standard or an investigational or biologic anticancer agent) within 14 days of initiation of study drug treatment.
  • Current enrollment in another clinical trial involving treatment and/or is receiving an investigational agent for any reason
  • Inability or unwillingness to comply with birth control requirements.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01997840

Contact: Gina Leone (617) 245-1311

United States, Georgia
Winship Cancer Institute Recruiting
Atlanta, Georgia, United States, 30322
Contact: Cathy Sharp    404-778-3811   
Principal Investigator: Sagar Lonial, MD         
United States, Indiana
Horizon Oncology Research Inc Recruiting
Lafayette, Indiana, United States, 47905
Contact: Kristen McKinley, RN    765-446-5111 ext 19155   
Principal Investigator: Wael Harb, MD         
United States, Massachusetts
Dana Farber Cancer Institute Recruiting
Boston, Massachusetts, United States, 02215
Contact: Catherine Flynn    617-632-3788   
Principal Investigator: Paul Richardson, MD         
Massachusetts General Hospital Recruiting
Boston, Massachusetts, United States, 02114
Contact: Chi La    617-724-5251   
Principal Investigator: Noopur Raje, MD         
United States, Ohio
Ohio State University, James Cancer Hospital Recruiting
Columbus, Ohio, United States, 43210
Contact: Katie Stamper    614-366-6386   
Principal Investigator: Ashley E Rosko, MD         
United States, Texas
Univ of Texas Health Science Center at San Antonio Recruiting
San Antonio, Texas, United States, 78229
Contact: Kathleen Cobb, RN    210-450-5893   
Principal Investigator: Steve Weitman, MD         
United States, Washington
Fred Hutchinson Cancer Research Center Recruiting
Seattle, Washington, United States, 98109
Contact: Cari Morin    206-667-6238   
Principal Investigator: William Bensinger, MD         
United States, Wisconsin
Medical College of Wisconsin Recruiting
Milwaukee, Wisconsin, United States, 53226
Contact: Marilyn Linde    414-805-4196   
Principal Investigator: Carlos Arce-Lara, MD         
Sponsors and Collaborators
Acetylon Pharmaceuticals Incorporated
  More Information

No publications provided

Responsible Party: Acetylon Pharmaceuticals Incorporated Identifier: NCT01997840     History of Changes
Other Study ID Numbers: ACE-MM-102
Study First Received: November 20, 2013
Last Updated: July 21, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Acetylon Pharmaceuticals Incorporated:
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Blood Protein Disorders
Hematologic Diseases
Dexamethasone acetate

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Blood Protein Disorders
Cardiovascular Diseases
Hematologic Diseases
Hemorrhagic Disorders
Hemostatic Disorders
Immune System Diseases
Immunoproliferative Disorders
Lymphoproliferative Disorders
Neoplasms by Histologic Type
Vascular Diseases
BB 1101
Dexamethasone 21-phosphate
Dexamethasone acetate
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Anti-Bacterial Agents
Anti-Infective Agents
Anti-Inflammatory Agents
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Autonomic Agents
Central Nervous System Agents processed this record on November 25, 2014